# Observational glomerulonephritis studies: 34 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials that are observational for glomerulonephritis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational glomerulonephritis studies: 34 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/glomerulonephritis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 34
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931170 | Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort Study | Pediatric Nephrology Research Consortium | Observational | Recruiting | IgA Nephropathy (IgAN), IgA Vasculitis, Idiopathic Immune Complex Glomerulonephritis, C3 Glomerulopathy, Membranous... | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931170) |
| November 12, 2026 | NCT07930676 | Early PLA2R Status in Severe Anti-PLA2R-mediated Membranous Nephropathy and Long Term Kidney Outcome. | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Membranous Nephropathy, Major Adverse Kidney Events | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07930676) |
| October 29, 2026 | NCT07904338 | Pilot STUDY to Monitor Ex-vivo the Biological Effects of the C3 Inhibitor, PEGCETACOPLAN, on Activation of Complement in Fluid Phase and on... | Mario Negri Institute for Pharmacological Research | Observational | Not yet recruiting | Glomerulopathy, C3G, Membranoproliferative Glomerulonephritis (MPGN) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904338) |
| October 23, 2026 | NCT07892651 | MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) | Sponsor not shown (see the record) | Observational | Not yet recruiting | Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)... | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892651) |
| August 25, 2026 | NCT07785739 | Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy | Assiut University | Observational | Not yet recruiting | Membranous Nephropathy, Nephrotic Syndrome, Kidney Diseases | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785739) |
| August 25, 2026 | NCT07783737 | China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study | AstraZeneca | Observational | Recruiting | Glomerulonephritis Kidney Transplant | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783737) |
| May 20, 2026 | NCT07598448 | A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain | Novartis Pharmaceuticals | Observational | Recruiting | Complement 3 Glomerulopathy | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598448) |
| May 14, 2026 | NCT07585981 | Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy. | Chinese PLA General Hospital | Observational | Recruiting | IgA Glomerulonephritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585981) |
| April 29, 2026 | NCT07555301 | Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy | Waid City Hospital, Zurich | Observational | Not yet recruiting | IgA Nephropathy (IgAN) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555301) |
| March 18, 2026 | NCT07481084 | IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection | Novartis Pharmaceuticals | Observational | Not yet recruiting | IgA Nephropathy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481084) |
| February 18, 2026 | NCT07416942 | Omics of Rituximab-resistance | Mario Negri Institute for Pharmacological Research | Observational | Not yet recruiting | Membranous Nephropathy | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416942) |
| February 18, 2026 | NCT07416162 | A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy | Novartis Pharmaceuticals | Observational | Recruiting | Paroxysmal Nocturnal Hemoglobinuria, C3 Glomerulopathy | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416162) |
| January 9, 2026 | NCT07330362 | The Clinical Application of Artificial Intelligence Assisted Renal Biopsy Diagnosis System. | Zhujiang Hospital | Observational | Recruiting | Chronic Glomerulonephritis, Chronic Kidney Disease | 2,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07330362) |
| June 8, 2025 | NCT07010250 | Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis | Assistance Publique - Hôpitaux de Paris | Observational | Recruiting | ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis... | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07010250) |
| April 30, 2025 | NCT06952426 | A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US | Novartis Pharmaceuticals | Observational | Recruiting | Immunoglobulin A Nephropathy | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06952426) |
| April 13, 2025 | NCT06926244 | RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN) | Assistance Publique - Hôpitaux de Paris | Observational | Recruiting | IgA Nephropathy (IgAN) | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926244) |
| February 12, 2025 | NCT06821919 | Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease (NETs - Neutrophil Traps) | Western Galilee Hospital-Nahariya | Observational | Recruiting | Diabetes Mellitus, Kidney Disease | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06821919) |
| January 24, 2025 | NCT06792448 | Biomarkers and Outcome Predictors of Pediatric Nephrotic Syndrome: A Genetic, Transcriptomic, and Secretome Multiomics Study | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Observational | Not yet recruiting | Nephrotic Syndrome Steroid-Dependent, Nephrotic Syndrome Steroid-Resistant, Nephrotic Syndrome in Children... | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06792448) |
| January 7, 2025 | NCT06760845 | Raman Spectroscopy Diagnosis of Kidney Diseases | Sponsor not shown (see the record) | Observational | Recruiting | IgA Nephropathy (IgAN), Membranous Nephropathy, Diabetic Nephropathy, Focal Segmental Glomerulosclerosis (FSGS) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06760845) |
| November 6, 2024 | NCT06676007 | A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA... | Sichuan Provincial People's Hospital | Observational | Recruiting | IgA Nephropathy (IgAN), Early Initial Therapy | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06676007) |
| March 18, 2024 | NCT06315504 | Circulating Factors in Nephrotic Syndrome | Sponsor not shown (see the record) | Observational | Not yet recruiting | Nephrotic Syndrome, Membranous Nephropathy, Minimal Change Disease, Primary Focal Segmental Glomerulosclerosis | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06315504) |
| February 5, 2024 | NCT06242327 | An Outcome Analysis of Primary Membranous Nephropathy | Mario Negri Institute for Pharmacological Research | Observational | Recruiting | Membranous Nephropathy | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06242327) |
| October 4, 2023 | NCT06065852 | National Registry of Rare Kidney Diseases | UK Kidney Association | Observational | Recruiting | Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis, Alport Syndrome... | 35,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06065852) |
| January 18, 2023 | NCT05688865 | Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis | Chinese University of Hong Kong | Observational | Recruiting | Membranous Nephropathy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05688865) |
| August 17, 2022 | NCT05505500 | Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome. | University of Michigan | Observational | Recruiting | Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy, Minimal Change Disease, Minimal... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05505500) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Mario Negri Institute for Pharmacological Research | 4 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
| University of Michigan | 2 |
| Sun Yat-sen University | 2 |
| Seoul National University Hospital | 1 |
| Chinese University of Hong Kong | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Zhujiang Hospital | 1 |
| Chinese PLA General Hospital | 1 |
| Assiut University | 1 |
| Western Galilee Hospital-Nahariya | 1 |
| UK Kidney Association | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 1 |
| Pediatric Nephrology Research Consortium | 1 |
| Waid City Hospital, Zurich | 1 |
| Sichuan Provincial People's Hospital | 1 |
| The Rogosin Institute | 1 |
| Ruijin Hospital | 1 |
| George (Beijing) Clinical Research Co. Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 10 |
| United States | 5 |
| Italy | 4 |
| France | 3 |
| South Korea | 2 |
| Hong Kong | 1 |
| Jordan | 1 |
| Canada | 1 |
| Israel | 1 |
| United Kingdom | 1 |
| Spain | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Security system companies in the United States](https://specstream.ai/data/businesses/security-system-companies/united-states)
- [Corporate gift suppliers in the United States](https://specstream.ai/data/businesses/corporate-gift-suppliers/united-states)
- [Packaging companies in the United States](https://specstream.ai/data/businesses/packaging-companies/united-states)
- [B2B quarry companies in the United States](https://specstream.ai/data/businesses/b2b-quarry-companies/united-states)
- [Irish pubs in the United States](https://specstream.ai/data/businesses/irish-pubs/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
